Psychiatr. praxi. 2020;21(2):66-72 | DOI: 10.36290/psy.2020.012

Current trends in treatment of generalised anxiety disorder

MUDr. Eliška Nosková1,2, MUDr. Antonín Šebela, Ph.D.1, MUDr. Pavla Stopková, Ph.D.1,2
1 Národní ústav duševního zdraví, Klecany
2 3. lékařská fakulta Univerzity Karlovy, Praha

Generalized anxiety disorder is described as an excessive and disproportionate anxiety and worry about minor matters in daily living, which are accompanied with wide spectrum of somatic symptoms. This review is focused primary on current guidelines and news in pharmacological treatment. Further it is focused on psychotherapy options and possibilities of clinical application of rTMS, or ketamin. After decades of relative stagnation the field of clinical testing is opening also for group of anxiety disorders. In our review we also overview current ongoing clinical trials, which show the possibilities of treatment generalised anxiety disorder in the future.

Keywords: generalised anxiety disorder, pharmacotherapy, psychotherapy.

Published: June 29, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nosková E, Šebela A, Stopková P. Current trends in treatment of generalised anxiety disorder. Psychiatr. praxi. 2020;21(2):66-72. doi: 10.36290/psy.2020.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slee A, Nazareth I, Bondaronek P, et alPharmacological treatments for generalised anxiety disorder: a systematic review and network meta‑analysis. The Lancet, 2019; 393(10173): 768-777. https://doi.org/10.1016/S0140-6736(18)31793-8 Go to original source... Go to PubMed...
    2. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association, 2013.
    3. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
    4. The World Health Organization's (2019) International Statistical Classification of Diseases and Related Health Problems (11th ed.; ICD-11).
    5. Spitzer RL, Kroenke K, Williams JBW, Löw, B.A. brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine 2006; 166(10): 1092-1097. https://doi.org/10.1001/archinte.166. 10. 1092; do českého jazyka zpracováno leden 2012. RBTLYR-11-236. Go to original source... Go to PubMed...
    6. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders, 1988; 14(1): 61-68. https://doi.org/10.1016/0165-0327(88)90072-9 Go to original source... Go to PubMed...
    7. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment‑resistant generalized anxiety disorder. Pharmacotherapy, 2010; 30(9): 942-951. https://doi.org/10.1592/phco.30. 9. 942 Go to original source... Go to PubMed...
    8. Gottschalk MG, Domschke K.Genetics of generalized anxiety disorder and related traits. Dialogues in Clinical Neuroscience - 2017; 19(2): 159-168 Go to original source...
    9. Findikl E, Camkurt MA, Azci F, et al. The diagnostic value of malondialdehyde, superoxide dismutase and catalase activity in drug naïve, first episode, non‑smoker generalized anxiety disorder patients. Clinical Psychopharmacology and Neuroscience, 2018; 16(1): 88-94. https://doi.org/10.9758/cpn.2018. 16. 1.88 Go to original source... Go to PubMed...
    10. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. International Journal of Neuropsychopharmacology, 2008; 11(6): 851-876. https://doi.org/10.1017/S1461145707008401 Go to original source... Go to PubMed...
    11. Costello H, Gould RL, Abrol E, Howard R. Systematic review and meta‑analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. BMJ Open 2019; 9(7): 1-16. https://doi.org/10.1136/bmjopen-2018-027925 Go to original source... Go to PubMed...
    12. Réus GZ, Fries GR, Stertz L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience, 2015; 300(May): 141-154. https://doi.org/10.1016/j.neuroscience.2015. 05. 018 Go to original source... Go to PubMed...
    13. Via E, Fullan MA, Goldberg X, et at. Ventromedial prefrontal cortex activity and pathological worry in generalised anxiety disorder. 2018;. British Journal of Psychiatry, 213(1): 437-443. https://doi.org/10.1192/bjp.2018.65 Go to original source... Go to PubMed...
    14. Delvecchio G, Stanley JA, Altamura AC, Brambilla P. Metabolic alterations in generalised anxiety disorder: A review of proton magnetic resonance spectroscopic studies. 2017; Epidemiology and Psychiatric Sciences, 26(6): 587-595. https://doi.org/10.1017/S2045796017000361 Go to original source... Go to PubMed...
    15. Sanjay J. Mathew, Rebecca B., et al. Hippocampal N‑Acetylaspartate Concentration and Response to Riluzole in Generalized Anxiety Disorder. 2008. Biol Psychiatry, 2008; May 1, 63(9): 891-898. Go to original source... Go to PubMed...
    16. Tyrer P. Against the Stream: Generalised anxiety disorder (GAD) - a redundant diagnosis. 2018. BJPsych Bulletin, 42(2); 69-71. https://doi.org/10.1192/bjb.2017.12 Go to original source... Go to PubMed...
    17. Regier DA, Narrow WE, Clarke DE, et al. DSM-5 field trials in the United States and Canada, part II: Test‑retest reliability of selected categorical diagnoses. 2013; American Journal of Psychiatry, 170(1): 59-70. https://doi.org/10.1176/appi.ajp.2012.12070999 Go to original source... Go to PubMed...
    18. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta‑analysis. 2019. The Lancet, 393(10173), 768-777. https://doi.org/10.1016/S0140-6736(18)31793-8 Go to original source... Go to PubMed...
    19. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive‑compulsive disorders. 2014. BMC Psychiatry, 14(SUPPL.1), 1-83. https://doi.org/10.1186/1471-244X-14-S1-S1 Go to original source... Go to PubMed...
    20. Guaiana G, Barbui C, Churchill R, et al. Hydroxyzine for generalised anxiety disorder. 2007. Cochrane Database of Systematic Reviews, (4). https://doi.org/10.1002/14651858.CD006815 Go to original source...
    21. Buoli M, Grassi S, Serati M, et al. Agomelatine for the treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy, 2017; 18(13): 1373-1379. https://doi.org/10.1080/14656566.2017.1359257 Go to original source... Go to PubMed...
    22. Bystritsky A, Kerwin L, Feusner JD, Vapnik K. A pilot controlle trial of bupripion XL versus escitalopram in generalized anxiety disored. Psychopharmacol Bull. 2008; 41(1): 46-51. Go to PubMed...
    23. Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence‑based treatment review. Expert Opinion on Pharmacotherapy, 2018; 19(10): 1057-1070. https://doi.org/10.1080/14656566.2018.1491966 Go to original source... Go to PubMed...
    24. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: A fixed dose, open label study. Journal of Psychopharmacology, 2005; 19(5): 483-487. https://doi.org/10.1177/0269881105056527 Go to original source... Go to PubMed...
    25. Rickels K, Doening R, Schweizer E, Hassman H. Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo‑Controlled Compariosn of Imipramine, Trazodone, and Diazepam. Arch Gen Psychiatry/VOL 50, NOV 1993. 1993; 50: 884-895. Go to original source... Go to PubMed...
    26. Qin B, Huang G, Yang Q, et al. Vortioxetine treatment for generalised anxiety disorder: A meta‑analysis of anxiety, quality of life and safety outcomes. BMJ Open, 2019; 9(11): 1-9. https://doi.org/10.1136/bmjopen-2019-033161 Go to original source... Go to PubMed...
    27. Gommoll C, Durgam S, Mathews M, et al. A double‑blind, randomized, placebo‑controlled, fixed‑dose phase iii study of vilazodone in patients with generalized anxiety disorder. Depression and Anxiety, 2015; 32(6): 451-459. https://doi.org/10.1002/da.22365 Go to original source... Go to PubMed...
    28. Durgam S, Gommoll C, Forero G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: A randomized, double‑blind, placebo‑controlled, flexible‑dose trial. Journal of Clinical Psychiatry, 2016; 77(12): 1687-1694. https://doi.org/10.4088/JCP.15m09885 Go to original source... Go to PubMed...
    29. Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: An updated systematic review and meta‑analysis. International Clinical Psychopharmacology, 2017; 32(1): 49-55. https://doi.org/10.1097/YIC.0000000000000147. Go to original source... Go to PubMed...
    30. Feltner D, Wittchen HU, Kavoussi R, et al. Long‑term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology, 2008; 23(1): 18-28. https://doi.org/10.1097/YIC.0b013e3282f0f0d7Další literatura u autorky a na www.psychiatriepropraxi.cz Go to original source... Go to PubMed...
    31. Markota M, Morgan RJ. Treatment of Generalized Anxiety Disorder with Gabapentin. Case Reports in Psychiatry, 2017; 1-4. https://doi.org/10.1155/2017/6045017 Go to original source... Go to PubMed...
    32. Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double‑blind, placebo‑controlled, parallel‑group studies. Journal of Clinical Psychopharmacology, 2008; 28(3): 308-316. https://doi.org/10.1097/JCP.0b013e318172b45f Go to original source... Go to PubMed...
    33. Aliyev NA, Aliyev ZN. Valproate (depakine‑chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double‑blind placebo‑controlled study. European Psychiatry, 2008; 23(2): 109-114. https://doi.org/10.1016/j.eurpsy.2007. 08. 001 Go to original source... Go to PubMed...
    34. Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive‑Compulsive Disorders. Current Psychiatry Reports, 2017; 19(12). https://doi.org/10.1007/s11920-017-0847-x Go to original source... Go to PubMed...
    35. Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: A systematic review and meta‑analysis of randomized controlled trials. Drug Design, Development and Therapy, 2016; 10: 259-276. https://doi.org/10.2147/DDDT.S89485 Go to original source... Go to PubMed...
    36. Hidalgo RB, Tupler LA, Davidson JRT. An effect‑size analysis of pharmacologic treatments for generalized anxiety disorder. Journal of Psychopharmacology, 2007; 21(8): 864-872. https://doi.org/10.1177/0269881107076996 Go to original source... Go to PubMed...
    37. Kasper S, Müller WE, Volz HP, et al. Silexan in anxiety disorders: Clinical data and pharmacological background. World Journal of Biological Psychiatry, 2018; 19(6): 412-420. https://doi.org/10.1080/15622975.2017.1331046 Go to original source... Go to PubMed...
    38. Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double‑blind, randomised, placebo‑controlled study. Australian and New Zealand Journal of Psychiatry, 2020; 54(3): 288-297. https://doi.org/10.1177/0004867419891246 Go to original source... Go to PubMed...
    39. Carl E, Witcraft SM, Kauffman BY, et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta‑analysis of randomized controlled trials. Cognitive Behaviour Therapy, 2020; 49(1): 1-21. https://doi.org/10.1080/16506073.2018.1560358 Go to original source... Go to PubMed...
    40. Stefan S, Cristea IA, Szentagotai Tatar A, David D. Cognitive‑behavioral therapy (CBT) for generalized anxiety disorder: Contrasting various CBT approaches in a randomized clinical trial. Journal of Clinical Psychology, 2019; 75(7): 1188-1202. https://doi.org/10.1002/jclp.22779 Go to original source... Go to PubMed...
    41. Kumar, V., Sattar, Y., Bseiso, A., Khan, S., & Rutkofsky, I. H. (2017). The Effectiveness of Internet-Based Cognitive Behavioral Therapy in Treatment of Psychiatric Disorders. Cureus, 9(8). https://doi.org/10.7759/cureus.1626 Go to original source... Go to PubMed...
    42. Oing T, Prescott J. Implementations of Virtual Reality for Anxiety-Related Disorders: Systematic Review. JMIR Serious Games. 2018;6(4):e10965. Published 2018 Nov 7. doi:10.2196/10965 Go to original source... Go to PubMed...
    43. Guitard, T., Bouchard, S., Bélanger, C., & Berthiaume, M. (2019). Exposure to a Standardized Catastrophic Scenario in Virtual Reality or a Personalized Scenario in Imagination for Generalized Anxiety Disorder. Journal of Clinical Medicine, 8(3), 309. https://doi.org/10.3390/jcm8030309 Go to original source... Go to PubMed...
    44. Cui, H., Jiang, L., Wei, Y., Li, W., Li, H., Zhu, J., Pang, J., Wang, J., & Li, C. (2019). Efficacy and safety of repetitive transcranial magnetic stimulation for generalised anxiety disorder: A meta-analysis. General Psychiatry, 32(5). https://doi.org/10.1136/gpsych-2019-100051 Go to original source...
    45. Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. https://doi.org/10.1177/0269881118762073 Go to original source... Go to PubMed...
    46. Sartori, S. B., & Singewald, N. (2019). Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacology and Therapeutics, 204, 107402. https://doi.org/10.1016/j.pharmthera.2019.107402 Go to original source... Go to PubMed...
    47. https://doi.org/10.1177/0269881118762073 Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.